virpax pharmaceuticals financials

Anthony Mack, Chairman and CEO of Virpax, will be giving … "As Chairman of the Audit Committee, it is with great … A brief financial summary of Virpax Pharmaceuticals Inc as well as the most significant critical numbers from each of its financial reports. Save . Sample 10-K Year-over-Year (YoY) Comparison. It is focused on pain management by developing and delivering non-opioid and non-addictive pharmaceutical products using new drug delivery systems and technology. Virpax Pharmaceuticals net worth as of April 20, 2021 is $0.02B. (1) Covers 1,009,505 shares of common stock issuable under the Virpax Pharmaceuticals, Inc. 2017 Equity Incentive Plan (the “2017 Plan”). Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments. Virpax Pharmaceuticals Inc (NASDAQ:VRPX) is actively using 26 technologies for its website, according to BuiltWith. Nasdaq 100. Key stats provide selected financials for rapid company overview including revenues, marketcap, P/E ratio, debt and much more. Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. Selected key stats of Virpax Pharmaceuticals, Inc. (VRPX) including 10 year stock price and latest news. Virpax Pharmaceuticals Inc. is a preclinical stage biopharmaceutical company. Get the detailed quarterly/annual income statement for Virpax Pharmaceuticals, Inc. (VRPX). VRPX: Virpax Pharmaceuticals, Inc. EPS. Virpax Pharmaceuticals, Inc. engages in developing pharmaceutical products for pain management by using new drug delivery systems. Jeffrey Gudin, MD, is co-founder and Executive Vice President at Virpax. Dr. Gudin completed both an anesthesiology residency and pain management fellowship at Yale University School of Medicine, and has been active in the pain management space as a clinician, consultant and researcher for more than 25 years. Mr. Mack founded his first pharmaceutical company, ProSolus Before founding VIRPAX in 2016, Mr. Mack founded SCILEX Pharmaceuticals and served as President and CEO until ZTlido was approved in … Virpax Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data. Virpax is a preclinical stage biopharmaceutical company focused on becoming a global leader in pain management by developing and … Virpax Pharmaceuticals had issued 1,800,000 shares in its public offering on February 17th. Virpax Pharmaceuticals Inc. Virpax Pharmaceuticals, Inc. operates as a biotech company. Phone Number 610.727.4597 Anthony P. Mack has more than 25 years of experience in the pharmaceutical and finance industries. On April 7, 2021, Virpax Pharmaceuticals, Inc. (the "Company") entered into an employment agreement with Christopher Chipman, the Company's Chief Financial Officer (the "Chipman Employment Agreement"). Anthony P Mack is Chairman/CEO at Virpax Pharmaceuticals Inc. See Anthony P Mack's compensation, career history, education, & memberships. VRPX: Virpax Pharmaceuticals, Inc. Greek Montage stock information. View the basic VRPX option chain and compare options of Virpax Pharmaceuticals, Inc. on Yahoo Finance. Virpax Pharmaceuticals Inc. company facts, information and financial ratios from MarketWatch. About. Rating as of Jun 16, 2021. Virpax Pharmaceuticals Inc (NASDAQ:VRPX) has 1 current employee profile, Founding Chairman & CEO Anthony P Mack. Virpax Pharmaceuticals net income from 2020 to 2021. Show section Mr. Mack founded his first pharmaceutical company ProSolus Pharmaceuticals in Anthony P. Mack has more than 25 years of experience in the pharmaceutical and finance industries. Prior to founding Virpax in 2016, Mr. Mack founded Scilex Pharmaceuticals and served as President and CEO until February 2018. Scilex was sold to a publicly traded company. Mr. Mack founded his first pharmaceutical company, ProSolus Pharmaceuticals, in 2009 where he served as President before selling the company to Mission Pharmacal in 2015. Mr. Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive, non-opioid pharmaceutical products for … The Company specializes in developing novel drug delivery systems across various pain indications. Anthony Mack, Chairman and CEO of Virpax, will … Virpax Pharmaceuticals Inc. is a preclinical stage biopharmaceutical company. Company profile for Virpax Pharmaceuticals Inc. including key executives, insider trading, ownership, revenue and average growth rates. The company is focused on developing pharmaceutical product candidates for pain management. Active Tech Count 26. Virpax Pharmaceuticals Reports 2021 First Quarter Results and Recent Developments. Get the latest EPS stock quote information from Zacks Investment Research. Virpax Pharmaceuticals operating income from 2020 to 2021. About Virpax Pharmaceuticals. Virpax Pharmaceuticals, Inc. Common Stock (VRPX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. -0.09 (-2.00%) DATA AS OF Apr 16, 2021 1:10 PM ET. Virpax Pharmaceuticals Inc () Stock Market info Recommendations: Buy or sell Virpax Pharmaceuticals stock? Virpax Pharmaceuticals' lock-up period expires on Monday, August 16th. Virpax Pharmaceuticals had issued 1,800,000 shares in its initial public offering on February 17th. The total size of the offering was $18,000,000 based on an initial share price of $10.00. WEST CHESTER, PA / ACCESSWIRE / February 16, 2021 / Virpax® Pharmaceuticals Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the pricing of its initial public offering of 1,800,000 shares of its common stock at a public offering price of $10.00 per share, for gross … Assess VRPX key financial ratios including the P/E Ratio, TTM and MRQ. Virpax Pharmaceuticals Inc (NASDAQ:VRPX) Connect to CRM . WEST CHESTER, PA / ACCESSWIRE / June 2, 2020 / Virpax® Pharmaceuticals Inc. ("Virpax"), a company specializing in developing pharmaceutical products that incorporate the use of novel drug delivery systems for pain management, today announced the appointment of Christopher M. Chipman, CPA, Chief Financial Officer. $4.41. Their stock opened with $10.00 in its Feb 16, 2021 IPO. Download PDF Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments. Virpax Pharmaceuticals Inc (NASDAQ:VRPX) is registered under the ticker NASDAQ:VRPX. It offers a transdermal metered-dose spray, an aerosol-based system that delivers active pharmaceutical ingredients (API) as a patch-in-a-can, and liposomal in hydrogel encapsulation that provides prolonged postoperative analgesia. Monthly Visits 4,354. The company is focused on developing pharmaceutical product candidates for pain management. Highlights. View detailed VRPX description & address. Virpax Pharmaceuticals Inc. Virpax Pharmaceuticals Inc. is a preclinical stage biopharmaceutical company. Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive, non-opioid pharmaceutical products for pain management, today announced that it will be presenting virtually at the upcoming LD Micro Invitational XI event on Wednesday, June 9, 2021 at 4:30 PM ET. Virpax Pharmaceuticals, Inc. engages in developing pharmaceutical products for pain management by using new drug delivery systems. Industry: Pharmaceuticals: Major. BERWYN, Pa.-- (BUSINESS WIRE)-- #pharma -- Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments. Virpax Pharmaceuticals, Inc. Common Stock (VRPX) Nasdaq Listed. The total size of the offering was $18,000,000 based on an initial share price of $10.00. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray. Free forex prices, toplists, indices and lots more. SEC Filings for Virpax Pharmaceuticals Inc. Summary Financials People Technology Signals & News. He is the Co-Founder and former CEO and Chairman of Synergy Pharmaceuticals and has developed broad and influential contacts throughout the biopharmaceutical, financial, banking and investor communities. Get the latest Price and Consensus Chart for Virpax Pharmaceuticals, Inc. from Zacks Investment Research Corporate Governance Virpax Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. Virpax Pharmaceuticals Engages Torreya Capital to Advise on Global Partnering Efforts Apr 22, 2021 VRPX: Virpax Pharmaceuticals, Inc. industry comparisons. The current operating profit margin for Virpax Pharmaceuticals as of December 31, 2020 is 0.00%. View VRPX: Virpax Pharmaceuticals, Inc.investment & stock information. Employee Profiles. Business Wire • … BERWYN, PA — Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX), announced its financial results for the quarter ended March 31, 2021, and other recent developments. But as . These include IPhone / Mobile Compatible, Viewport Meta, and SPF. Free forex prices, toplists, indices and lots more. Headline. VRPX updated stock price target summary. Virpax Pharmaceuticals Inc. SEC filings breakout by MarketWatch. Scilex was sold to a publicly traded company. BERWYN, Pa.--(BUSINESS WIRE)-- Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments.“We successfully completed our initial public offering (IPO) of 1,800,000 shares of our common stock in mid-February and immediately began our IND enabling … Virpax Pharmaceuticals Inc. SEC filings breakout by MarketWatch. In addition, pursuant to Rule 416(c) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also covers an indeterminate amount of interests to be offered or sold pursuant to the employee benefit … Number of Employee Profiles 1. Virpax Pharmaceuticals, Inc. Common Stock (VRPX) Revenue EPS : Back to VRPX Overview ©2020, EDGAR®Online, a division of Donnelley Financial Solutions. Virpax Pharmaceuticals had issued 1,800,000 shares in its initial public offering on February 17th. The total size of the offering was $18,000,000 based on an initial share price of $10.00. After the expiration of Virpax Pharmaceuticals' lock-up period, major shareholders and company insiders will be able to sell their shares of the company. S-1. Virpax Pharmaceuticals (VRPX) stock price, charts, trades & the US's most popular discussion forums. View differences made from one to another to evaluate Virpax Pharmaceuticals, Inc.'s financial trajectory. Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing non-addictive, non-opioid pharmaceutical products for pain management, today announced that it will be presenting virtually at the upcoming LD Micro Invitational XI event on Wednesday, June 9, 2021 at 4:30 PM ET. Virpax Pharmaceuticals is committed to developing products that manage pain and all its complexities, while minimizing risks to patients and society. Monthly Visits Growth -6.93%. Fund performance data provided by Lipper. It is focused on pain management by developing and delivering non-opioid and non-addictive pharmaceutical … June 2, 2020 Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products that incorporate the use of novel drug delivery systems for pain management, today announced the appointment of Christopher M. Chipman, CPA, Chief Financial … finance.yahoo.com - June 2 at 12:36 PM. VRPX: Virpax Pharmaceuticals, Inc. - Insider Transactions Get the latest Insider Transactions for Virpax Pharmaceuticals, Inc. from Zacks Investment Research Virpax Pharmaceuticals net profit margin from 2020 to 2021. All quotes delayed a minimum of 15 minutes. Prior to founding Virpax in 2016, Mr. Mack founded Scilex Pharmaceuticals and served as President and CEO until February 2018. Prior to founding Virpax in 2016, Mr. Mack founded Scilex Pharmaceuticals and served as President and CEO until February 2018. The Income Statement (earnings report) for Virpax Pharmaceuticals Inc. Find the company's financial performance, revenue, and more. With Virpax Pharmaceuticals stock trading at $6.45 per share, the total value of Virpax Pharmaceuticals stock (market capitalization) is $29.08M. Summary Financials People Technology Signals & News. Access detailed quarterly and annual financial reports for Virpax Pharmaceuticals Inc. View the balance sheet, income statement, cash flow and more. Quote and financial data from Refinitiv. Pain is a universal … Access detailed quarterly and annual financial reports for Virpax Pharmaceuticals Inc. View the balance sheet, income statement, cash flow and more. Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Virpax Pharmaceuticals share forecasts, stock quote and buy / sell signals below.According to present data Virpax Pharmaceuticals's VRPX shares and potentially its market environment have … View the latest VRPX income statement, balance sheet, and financial ratios. Scilex was sold to a publicly traded company. The company is focused on developing pharmaceutical product candidates for pain management. View the VRPX U.S. Securities and Exchange Commission reporting information. Virpax Pharmaceuticals stock was originally listed at a price of $6.53 in Feb 17, 2021. Virpax Pharmaceuticals Description. Annual stock financials by MarketWatch. VIRPAX PHARMACEUTICALS, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for VIRPAX PHARMACEUTICALS, INC. Stock | VRPX | US9282511073 Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. BERWYN, Pa.-- (BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other rec... 1 month ago - Business Wire Virpax Pharmaceuticals Engages Torreya Capital to Advise on Global Partnering Efforts Please refer to the Stock Price Adjustment Guide for more information on our historical prices. 10/09/2020. SEC Filings provided by EDGAR Online, Inc. Prev Page Next Page. Get a brief overview of VIRPAX PHARMA INC financials with all the important numbers. The current price to book ratio for Virpax Pharmaceuticals as of May 28, 2021 is 2.37. Virpax Pharmaceuticals, Inc. CIK: 1708331. Their latest funding was raised on Feb 16, 2021 from a Series C round. Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. WEST CHESTER, PA / ACCESSWIRE / February 19, 2021 / Virpax Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the closing of its initial public offering of 1,800,000 shares of its common stock at a public offering price of $10.00 per share, for gross proceeds of $18.0 … Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. Virpax Pharmaceuticals (VRPX) stock price, charts, trades & the US's most popular discussion forums. VIRPAX PHARMACEUTICALS, INC. : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted. Virpax Pharmaceuticals Inc (NASDAQ:VRPX) has raised a total of $20.4M in funding over 3 rounds. Virpax Pharmaceuticals Inc. Virpax Pharmaceuticals, Inc. operates as a biotech company. N/A. Get the latest Greek Montage stock quote information from Zacks Investment Research VRPX: Virpax Pharmaceuticals, Inc. - Price and Consensus Chart. 10/09/2020. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. most relevant news about virpax pharmaceuticals, inc. 05/18: virpax pharmaceuticals : reports 2021 first quarter results and recent developm.. Highlights. Its products include metered-dose spray, liposomal gel … Virpax Pharmaceuticals is a company that develops products for pain management. The Company specializes in developing novel drug delivery systems across various pain indications. Data is currently not available. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for. View the VRPX U.S. Securities and Exchange Commission reporting information. DGAP-News: Virpax(R) Pharmaceuticals Inc. / Key word(s): IPO17.02.2021 / 05:47 The issuer is solely responsible for the content of this announcement.Virpax(R) Pharmaceuticals Announces Pricing of Initial Public OfferingWEST CHESTER, PA, February 16, 2021 - Virpax(R) Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical … Chairman + CEO Anthony P. Mack has more than 25 years of experience in the pharmaceutical and finance industries. Virpax Pharmaceuticals (NASDAQ:VRPX) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior stock?We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings. Add to … Operating income can be defined as income after operating expenses have been deducted and … Virpax Pharmaceuticals to Present at LD Micro Invitational XI Event on Wednesday, June 9th at 4:30 PM ET. Virpax Pharmaceuticals Inc. VRPX. Find out the revenue, expenses and profit or loss over the last fiscal year. Morningstar Rating. Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced its financial results for the quarter ended March 31, 2021, and other recent developments. Net profit margin can be defined as net Income as a portion of total sales revenue. View the latest VRPX financial statements, income statements and financial ratios. Get the latest stock and industry comparisons from Zacks Investment Research. Virpax Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Our proprietary delivery systems will reinvent how patients and prescribers manage pain worldwide. finance.yahoo.com - May 18 at 12:44 PM. Registration Statement. About. Get the latest VRPX: Virpax Pharmaceuticals, Inc. detailed stock quotes, stock data, Real-Time ECN, charts, stats and more..